<DOC>
	<DOCNO>NCT00081549</DOCNO>
	<brief_summary>This study Phase I/II study . In Phase I study , objective determine maximum tolerate dose ( MTD ) combination therapy Aroplatin gemcitabine ( Gemzar® ) subject unresectable , locally advanced and/or metastatic pancreatic cancer . In Phase II , primary objective evaluate survival therapy Aroplatin gemcitabine identify MTD subject unresectable , locally advanced and/or metastatic pancreatic cancer . Secondary objective evaluate severity quantity adverse event determine proportion non-progressors progression-free interval .</brief_summary>
	<brief_title>Aroplatin Gemcitabine Patients With Advanced Pancreatic Cancer Resistant Standard Therapies</brief_title>
	<detailed_description>Phase I Primary Objective : - Determine maximum tolerate dose ( MTD ) combination therapy Aroplatin gemcitabine ( Gemzar® ) subject unresectable , locally advanced and/or metastatic pancreatic cancer . Phase II Primary Objective : - Evaluate survival therapy Aroplatin gemcitabine MTD subject unresectable , locally advanced and/or metastatic pancreatic cancer . Phase II Secondary Objective : - Evaluate severity quantity adverse event determine proportion non-progressors progression-free interval .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>bis-neodecanoato-1,2-diaminocyclohexaneplatinum ( II )</mesh_term>
	<criteria>Inclusion Criteria Pancreatic cancer ( AJCC Stage IIIV ) ; Unresectable cancer ; Measurable disease ( RECIST criterion ) ; No prior therapy ; ECOG Score 02 Life expectancy great equal three month ; Adequate hematopoietic , liver renal function ; Women childbearing potential must negative urine/serum pregnancy test ; Signed write informed consent ; Subjects must willing follow course treatment/observation followup . Prior therapy pancreatic cancer ; Previously diagnose brain metastasis symptomatic require active therapy ; Other cancer within last five year , exception adequately treat conebiopsied insitu carcinoma cervix uteri basal squamous cell carcinoma skin ; Any serious concomitant medical mental illness require intense therapy interfere participation study Primary secondary immunodeficiency , use corticosteroid immunosuppressive medication ; Women must pregnant breastfeeding ; Participation clinical trial involve investigational drug within one month enrollment present study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Neoplasms Pancreatic</keyword>
	<keyword>Pancreas Cancer</keyword>
	<keyword>Pancreas Neoplasms</keyword>
	<keyword>Pancreatic Tumor</keyword>
	<keyword>Pancreas Tumor</keyword>
	<keyword>Unresectable</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Refractory</keyword>
</DOC>